Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Clinical trial protocols often focus on the clinical objectives of the trial, without considering the implications of the design on the patients participating in the trial – this can contribute to lower trial participation, increased drop-out rates, and reduced operational efficiency. Could incorporating the patient voice in clinical trial design and execution address these issues and provide key insight for innovations in healthcare?
Register Free:
https://www.pharmexec.com/pe/navigating-healthcare
Event Overview:
In the realm of healthcare, patients are now more involved in their own care, with easy access to information through the internet and the use of new technologies that empower them to generate and share data. Patients are not only the beneficiaries of scientific knowledge but are creators of scientific knowledge. As a result, (bio)pharma companies are recognizing the potential benefits of engaging with highly motivated patients and patient organizations. This approach not only reduces costs but also enhances the success of clinical trials.
Join this webinar to learn more about including patients as partners in clinical research and utilizing technology to collect relevant patient-centric, real-world data to improve the design and outcomes of clinical trial research studies, advocate for patient equity, and advance scientific and drug discovery.
Key Learning Objectives
Who Should Attend
Full Agenda
Thursday, March 21st:
10:00 am EDT Addressing Diversity in Patient Recruitment for Clinical Research
Katherine Vandebelt, Global Vice President, Clinical Innovation; Oracle, and other non-Oracle speakers.
11:00 am EDT Addressing Enrollment and Trial Inefficiencies With Patients as Partners
Rebecca Nash, Principal, Real-World Evidence; Oracle
Kathy Beusterien, Senior Research Scientist; Oracle, and other non-Oracle speakers.
12:00 pm EDT Do Decentralized Trials Still Offer Clinical Precision in Challenging Patient Populations?
Gillian Worman, Director, Product Strategy; Oracle
David Blackman, Executive Director, Digital Trials Strategy; Oracle, and other non-Oracle speakers.
1:00 pm EDT Advancing Drug Discovery and Treatment Options with Patients and Citizen Science
Amy Sorrells, Senior Director; Oracle, and other non-Oracle speakers.
2:00 pm EDT Accelerating Precision Oncology with Artificial Intelligence
Elise Berliner, Global Senior Principal of Real-World Evidence Strategy; Oracle, and other non-Oracle speakers.
Speakers:
Katherine Vandebelt
Global Vice President, Clinical Innovation
Oracle
Rebecca Nash
Principal, Real-World Evidence
Oracle
Kathy Beusterien
Senior Research Scientist
Oracle
Gillian Worman
Director, Product Strategy
Oracle
David Blackman
Executive Director, Digital Trials Strategy
Oracle
Amy Sorrells
Senior Director
Oracle
Elise Berliner
Global Senior Principal of Real-World Evidence Strategy
Oracle
Register Free:
https://www.pharmexec.com/pe/navigating-healthcare
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.
2 Commerce Drive
Cranbury, NJ 08512